Investigational Drug Information for Miricorilant
✉ Email this page to a colleague
What is the development status for investigational drug Miricorilant?
Miricorilant is an investigational drug.
There have been 8 clinical trials for Miricorilant.
The most recent clinical trial was a Phase 1 trial, which was initiated on October 31st 2019.
The most common disease conditions in clinical trials are Non-alcoholic Fatty Liver Disease, Fatty Liver, and Weight Gain. The leading clinical trial sponsors are Corcept Therapeutics and [disabled in preview].
There are five US patents protecting this investigational drug and sixty international patents.
Summary for Miricorilant
| US Patents | 5 |
| International Patents | 60 |
| US Patent Applications | 32 |
| WIPO Patent Applications | 23 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 1 (2019-10-31) |
| Vendors | 10 |
Recent Clinical Trials for Miricorilant
| Title | Sponsor | Phase |
|---|---|---|
| A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH) | Corcept Therapeutics | Phase 2 |
| Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant | Corcept Therapeutics | Phase 1 |
| Phase 1 Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant | Corcept Therapeutics | Phase 1 |
Clinical Trial Summary for Miricorilant
Top disease conditions for Miricorilant
Top clinical trial sponsors for Miricorilant
US Patents for Miricorilant
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Miricorilant | ⤷ Sign Up | Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome | Corcept Therapeutics, Inc. (Menlo Park, CA) | ⤷ Sign Up |
| Miricorilant | ⤷ Sign Up | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists | Corcept Therapeutics, Inc. (Menlo Park, CA) | ⤷ Sign Up |
| Miricorilant | ⤷ Sign Up | Pyrimidine cyclohexyl glucocorticoid receptor modulators | Corcept Therapeutics, Inc. (Menlo Park, CA) | ⤷ Sign Up |
| Miricorilant | ⤷ Sign Up | Pyrimidine cyclohexyl glucocorticoid receptor modulators | Corcept Therapeutics, Inc. (Menlo Park, CA) | ⤷ Sign Up |
| Miricorilant | ⤷ Sign Up | Pyrimidine cyclohexyl glucocorticoid receptor modulators | Corcept Therapeutics, Inc. (Menlo Park, CA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Miricorilant
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Miricorilant | Australia | AU2017210156 | 2036-01-19 | ⤷ Sign Up |
| Miricorilant | Canada | CA3011728 | 2036-01-19 | ⤷ Sign Up |
| Miricorilant | European Patent Office | EP3405101 | 2036-01-19 | ⤷ Sign Up |
| Miricorilant | Spain | ES2861524 | 2036-01-19 | ⤷ Sign Up |
| Miricorilant | Israel | IL260687 | 2036-01-19 | ⤷ Sign Up |
| Miricorilant | Japan | JP2019503495 | 2036-01-19 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
